- Home
- MUJ vs UPB Comparison
MUJ vs UPB Comparison
Compare MUJ & UPB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MUJ
- UPB
- Stock Information
- Founded
- MUJ 1998
- UPB 2021
- Country
- MUJ United States
- UPB United States
- Employees
- MUJ N/A
- UPB N/A
- Industry
- MUJ Investment Bankers/Brokers/Service
- UPB
- Sector
- MUJ Finance
- UPB
- Exchange
- MUJ Nasdaq
- UPB NYSE
- Market Cap
- MUJ 573.3M
- UPB 521.3M
- IPO Year
- MUJ N/A
- UPB 2024
- Fundamental
- Price
- MUJ $10.81
- UPB $10.88
- Analyst Decision
- MUJ
- UPB Strong Buy
- Analyst Count
- MUJ 0
- UPB 4
- Target Price
- MUJ N/A
- UPB $56.50
- AVG Volume (30 Days)
- MUJ 108.0K
- UPB 422.3K
- Earning Date
- MUJ 01-01-0001
- UPB 08-14-2025
- Dividend Yield
- MUJ 4.36%
- UPB N/A
- EPS Growth
- MUJ N/A
- UPB N/A
- EPS
- MUJ N/A
- UPB N/A
- Revenue
- MUJ N/A
- UPB $2,296,000.00
- Revenue This Year
- MUJ N/A
- UPB N/A
- Revenue Next Year
- MUJ N/A
- UPB N/A
- P/E Ratio
- MUJ N/A
- UPB N/A
- Revenue Growth
- MUJ N/A
- UPB N/A
- 52 Week Low
- MUJ $9.74
- UPB $5.14
- 52 Week High
- MUJ $11.70
- UPB $29.46
- Technical
- Relative Strength Index (RSI)
- MUJ 40.83
- UPB N/A
- Support Level
- MUJ $10.73
- UPB N/A
- Resistance Level
- MUJ $10.86
- UPB N/A
- Average True Range (ATR)
- MUJ 0.08
- UPB 0.00
- MACD
- MUJ -0.00
- UPB 0.00
- Stochastic Oscillator
- MUJ 36.36
- UPB 0.00
About MUJ Blackrock MuniHoldings New Jersey Quality Fund Inc.
BlackRock MuniHoldings New Jersey Quality Fund Inc is a closed-end management investment company. The investment objective of the company is to provide shareholders with current income exempt from U.S. federal income tax and New Jersey personal income taxes. The fund invests in a portfolio of long-term, investment-grade New Jersey municipal obligations.
About UPB UPSTREAM BIO INC
Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine that is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases.